Refobacin Revision-3 Bone Cement Post-Market Study

Inclusion Criteria: * Patient is 18 years or older and skeletally mature. * Patient is capable of understanding the surgeon's explanations and following his/her instructions, able and willing to participate in the follow-up program. * Patient gave consent to take part in the study by signing the Ethics Committee approved Informed Consent Form (ICF). * Patient who underwent or will undergo a hip or knee revision surgery with a Zimmer Biomet implant and the Refobacin® Revision-3 Bone Cement. * Patient meets at least one of the following indications, as stated in the Instructions for Use (IFU): * Patients requires a revision operation resulting from aseptic loosening of the prosthesis and/or infection of the prosthesis by gentamicin and/or clindamycin sensitive strains. * Patients undergoing a two-stage revision that requires the fabrication and fixation of short-term total or hemi joint StageOne™ spacers. The device is intended for use in conjunction with systemic antimicrobial therapy (standard approach to an infection). Additional inclusion criteria for patients receiving a StageOne™ spacer, as stated in the IFU: * Implantation period of a maximum of 180 days. * The molded temporary prosthesis is only indicated for patients who will consistently use traditional mobility assist devices (e.g. crutches, walkers) throughout the implant period. Exclusion Criteria: * Patient is unwilling or unable to give consent or to comply with the follow-up program. * Patient is known to be pregnant or breastfeeding. * Patient has any condition that would, in the judgment of the Investigator, place the patient at undue risk or interfere with the study. * Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, anticipated to be non-compliant). * Patient has plans to relocate during the study follow-up period. * As stated in the IFU, patient with known hypersensitivity to gentamicin and/or clindamycin and/or to other constituents of the bone cement. * Additional exclusion criteria for patients receiving a StageOne™ spacer, as stated in the IFU: * The infected Total Hip/Knee Replacement (THR/TKR) devices cannot be removed. * A systemic or secondary remote infection is expected or confirmed. * Lack of adequate bone structure precludes adequate support of the prosthesis in the proximal femur or acetabular region, or * Lack of adequate competence (anatomical and functional) of peripheral ligamentous apparatus and extensor mechanism. * The patient is sensitive (allergic) to aminoglycosides.